Drug Profile
Research programme: interleukin 4 antagonist - Apogenix/German Cancer Research Center
Alternative Names: APG201; IL-4 blockerLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Apogenix
- Developer Apogenix; German Cancer Research Center
- Class Proteins
- Mechanism of Action Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Parenteral)
- 29 Jul 2009 Preclinical trials in Solid tumours in Germany (Parenteral)